John Hancock Multifactor Materials ETF
JHMA
JHMA was delisted on the 24th of October, 2022.
0 hedge funds and large institutions have $0 invested in John Hancock Multifactor Materials ETF in 2022 Q4 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 7 closing their positions.
100% less funds holding
Funds holding: 8 → 0 (-8)
100% less capital invested
Capital invested by funds: $21.6M → $0 (-$21.6M)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 7
154.94% less ownership
Funds ownership: 154.94% → 0% (-155%)
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Manulife (Manufacturers Life Insurance)
Canada,
Ontario, Canada
|
-$19.2M |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$1.26M |
| 3 |
FA
Faithward Advisors
Lancaster,
Pennsylvania
|
-$875K |
| 4 |
LPL Financial
San Diego,
California
|
-$241K |
| 5 |
Osaic Holdings
Scottsdale,
Arizona
|
-$29K |
JHMA Hedge Fund Activity: Q4 2022 in Review
0 of the 6,240 institutional investors tracked by Wall St. Rank reported a position in John Hancock Multifactor Materials ETF (JHMA) for Q4 2022, worth a combined $0 — down 100% from $21.6M a quarter earlier.
Sellers outnumbered buyers: 7 funds closed out of JHMA and 0 opened new positions — a net loss of 7 holders — while 0 trimmed existing stakes and 0 added.
The largest seller was Manulife (Manufacturers Life Insurance), exiting entirely with an estimated $19.2M sold.
- 0 institutional investors held John Hancock Multifactor Materials ETF (JHMA) as of Q4 2022, down from 8 in Q3 2022.
- Funds reported $0 of John Hancock Multifactor Materials ETF stock for Q4 2022, down 100% quarter-over-quarter.
- 0 funds opened new John Hancock Multifactor Materials ETF positions in Q4 2022 and 7 closed out, a net change of -7 holders.
- The largest John Hancock Multifactor Materials ETF seller in Q4 2022 was Manulife (Manufacturers Life Insurance), an estimated $19.2M sold.
Based on aggregated 13F filings for Q4 2022.